Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV.
Journal of Cystic Fibrosis(2019)
摘要
LUM/IVA significantly reduced PEx, even in patients without early lung function improvement.
更多查看译文
关键词
Cystic fibrosis,Pulmonary exacerbations,Percent predicted forced expiratory volume in 1 s,Lumacaftor,Ivacaftor
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络